Loading...
  • treprostinil
  • CDC conducted a retrospective investigation with the assistance of several state health departments and the cooperation of seven PAH treatment centers to determine the relative rates of BSI in a sample of patients treated with IV treprostinil and IV epoprostenol during 2003--2006. (cdc.gov)
  • This report describes the results of that investigation, which indicated that, based on combined data from seven separate PAH treatment centers, pooled mean rates of BSI (primarily gram-negative BSI) were significantly higher for patients on treprostinil than for those on epoprostenol. (cdc.gov)
  • A BSI was defined as any positive blood culture result for a patient receiving IV epoprostenol or IV treprostinil as reported from a clinical laboratory or by a health-care provider in the medical record during the period for which data were collected. (cdc.gov)
  • A total of 51,183 medicine days were reported from the seven centers for IV treprostinil and 201,158 from five centers for IV epoprostenol. (cdc.gov)
  • A total of 144 BSIs were identified (57 among patients on IV treprostinil and 87 among patients on IV epoprostenol). (cdc.gov)
  • Fourteen different organisms were found in BSIs among patients on IV epoprostenol (nine gram positive, four gram negative, and one acid fast bacillus), and 18 different organisms were found in BSIs among patients on IV treprostinil (seven gram positive, 10 gram negative, and one acid fast bacillus). (cdc.gov)
  • Stability
  • This study assessed stability and determined shelf-life of epoprostenol XX. (ersjournals.com)
  • Stability of epoprostenol XX, either diluted for immediate use and tested at 25°C, 30°C and 40°C for up to 72 h, or following storage for up to 8 days at 5°C after reconstitution and immediate dilution with further exposure at 25°C and 30°C for up to 48 h, was assessed at 3,000, 15,000 and 60,000 ng/mL. (ersjournals.com)
  • dose
  • The usual starting dose for adults is 4 nanograms of epoprostenol for each kilogram of body weight, for each minute it is given. (drugs.com)
  • After 2 years (epoprostenol dose 32 ng/kg/min) she was in class II with a good effort tolerance (6MWD 490 m), and a second invasive evaluation documented an improvement of hemodynamics (mPAP 26 mmHg, CI 2.9 l/min/m2, PVR 4.7 WU). (medcraveonline.com)
  • found
  • No evidence of platelet dysfunction or an increase in surgical bleeding after administration of inhaled epoprostenol has been found. (wikipedia.org)
  • further
  • The relative potency of reconstituted and immediately diluted epoprostenol XX after storage for 8 days at 5°C was ≥98% and remained ≥90% after further storage for 24-48h at 25°C or 30°C, depending on concentration. (ersjournals.com)